BDTX-1535 program to be advanced into pivotal development based on robust Ph 2 clinical data from EGFRm NSCLC patients October 15, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC October 15, 2024
US FDA Approves Perioperative Treatment of Neoadjuvant Opdivo and Chemo Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC October 8, 2024
Preliminary safety data from the Ph 1b portion of the BGBC016 study in 1L NSCLC patients announced October 8, 2024
BLA submitted for accelerated approval for Telisotuzumab Vedotin (Teliso-V) in Previously Treated NSCLC with c-Met protein overexpression based on Ph 2 LUMINOSITY trial (M14-239) data October 2, 2024
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer October 2, 2024
Initial Ph 2 Data of BDTX-1535 in Patients with Recurrent EGFRm NSCLC with Classical, Non-classical, and C797S Resistance Mutations Announced October 1, 2024
KEYTRUDA Receives New Approvals in Japan for perioperative Patients With NSCLC and in Radically Unresectable Urothelial Carcinoma October 1, 2024
Patient Recruitment Discontinued in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in NSCLC September 18, 2024
Datopotamab deruxtecan showed mOS of 14.6 months in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial September 18, 2024
Global Launch of Artemia Ph 3 Registration Study for Cancer Vaccine Tedopi® in 2L NSCLC Cancer Announced September 18, 2024
Encouraging results from expansion part of Ph 1/2 SOHO-01 study of BAY 2927088 in advanced HER2-mutant NSCLC announced September 17, 2024
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced NSCLC September 17, 2024
Ph 2 THIO-101 trial results show THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC September 17, 2024
Ivonescimab Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab in 1L PD-L1+ve Advanced NSCLC patients in China September 10, 2024
Novel computational pathology-based TROP2 biomarker for Dato-DXd was predictive of clinical outcomes in patients with NSCLC in TROPION-Lung01 September 10, 2024
Ph 3 KEYNOTE-867 trial in NSCLC and KEYNOTE-630 Trial in cSCC to be discontinued based on DMC recommendations September 3, 2024
Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage NSCLC September 3, 2024
First patient enrolled in Ph 3 SOHO-02 trial of BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations September 3, 2024
European Commission Approves BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adult patients with advanced NSCLC with a BRAFV600E mutation September 3, 2024
European Commission approves RYBREVANT (amivantamab) + chemo for adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy September 3, 2024
